Prevalence of beryllium sensitization in patients diagnosed with sarcoidosis

Détails

ID Serval
serval:BIB_75D4A641B788
Type
Actes de conférence (partie): contribution originale à la littérature scientifique, publiée à l'occasion de conférences scientifiques, dans un ouvrage de compte-rendu (proceedings), ou dans l'édition spéciale d'un journal reconnu (conference proceedings).
Sous-type
Abstract (résumé de présentation): article court qui reprend les éléments essentiels présentés à l'occasion d'une conférence scientifique dans un poster ou lors d'une intervention orale.
Collection
Publications
Titre
Prevalence of beryllium sensitization in patients diagnosed with sarcoidosis
Titre de la conférence
ERS 22nd Annual Congress, Vienna, Austria 1-5 September 2012
Auteur(s)
Lazor Romain, Aubert Vincent, Dorribo Victor, Chagnon Krief Peggy, Ottesen Montangero Sandrine, Wild Pascal, Bieler Gilles, Geiser Thomas, Valeyre Dominique, Berode Michèle, Danuser Brigitta, Orphan Lung Diseases
Collaborateur(s)
Swiss Group for Interstitial
ISBN
0903-1936
Statut éditorial
Publié
Date de publication
2012
Volume
40
Série
European Respiratory Journal
Pages
659S
Langue
anglais
Résumé
Occupational exposure to beryllium (Be) may lead to development of Be-specific CD4+ T-cell immune response and occurrence of a granulomatous disorder called chronic beryllium disease (CBD). Due to similar clinical pictures, CBD may be misdiagnosed as sarcoidosis if Be exposure (BeE) and Be sensitization (BeS) are not looked for. To determine whether some patients diagnosed as sarcoidosis may have undetected CBD, we screened a retrospective cohort of patients with sarcoidosis for BeE and BeS. BeE was assessed through a self-administered questionnaire and a standardized occupational health interview. BeS was assessed using CFSE flow cytometry developed as an alternative to the classical Be lymphocyte proliferation test (BeLPT). 159 patients recorded in a Swiss interstitial lung disease registry with a diagnosis of sarcoidosis were enrolled through their pulmonary physician and received a screening questionnaire. 68 filled questionnaires were returned. 28/68 patients had positive screening. 24/28 underwent an occupational health interview. BeE was considered probable in 6/24 and possible in 18/24. Using CFSE flow cytometry, BeS was detected in 7/24 of these patients (4/6 with probable BeE and 3/18 with possible BeE). BeS testing by CFSE flow cytometry was positive in 5/6 controls with proven CBD and positive BeLPT, and negative in 10 healthy subjects. Conclusions: the minimal rate of BeE and BeS in an unselected population of patients with sarcoidosis was 7/159 (4.4%), suggesting misdiagnosed CBD. A
screening questionnaire could help to detect BeE in patients diagnosed with sarcoidosis, and prompt investigations in search of CBD. CFSE flow cytometry may be an alternative to BeLPT to document BeS.
Mots-clé
Beryllium , Berylliosis , Occupational Exposure , Sarcoidosis , Switzerland ,
Création de la notice
02/09/2014 13:08
Dernière modification de la notice
20/08/2019 15:33
Données d'usage